What is Zacks Research's Estimate for JAZZ Q2 Earnings?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) - Equities research analysts at Zacks Research issued their Q2 2025 earnings estimates for Jazz Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 27th. Zacks Research analyst S. Ganoria anticipates that the specialty pharmaceutical company will earn ($8.76) per share for the quarter. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals' Q3 2025 earnings at $4.73 EPS, Q4 2025 earnings at $4.71 EPS, FY2025 earnings at $1.49 EPS, Q1 2026 earnings at $3.62 EPS, Q2 2026 earnings at $4.29 EPS, Q3 2026 earnings at $5.01 EPS, Q4 2026 earnings at $5.18 EPS, FY2026 earnings at $18.09 EPS, Q1 2027 earnings at $3.72 EPS and FY2027 earnings at $18.99 EPS.

Several other brokerages have also recently issued reports on JAZZ. HC Wainwright lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Barclays reissued an "overweight" rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded up $0.02 during mid-day trading on Friday, hitting $108.28. The company's stock had a trading volume of 977,559 shares, compared to its average volume of 838,951. The firm has a 50-day moving average price of $109.72 and a 200 day moving average price of $121.37. The stock has a market capitalization of $6.67 billion, a price-to-earnings ratio of 15.25, a PEG ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business's revenue for the quarter was down .5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.68 EPS.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of JAZZ. Barclays PLC increased its position in Jazz Pharmaceuticals by 19.1% during the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after acquiring an additional 6,289 shares during the period. Blue Trust Inc. increased its position in Jazz Pharmaceuticals by 83.7% during the fourth quarter. Blue Trust Inc. now owns 1,868 shares of the specialty pharmaceutical company's stock worth $230,000 after acquiring an additional 851 shares during the period. Robeco Institutional Asset Management B.V. increased its position in Jazz Pharmaceuticals by 20.3% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 201,304 shares of the specialty pharmaceutical company's stock worth $24,791,000 after acquiring an additional 33,948 shares during the period. Institute for Wealth Management LLC. bought a new position in Jazz Pharmaceuticals during the fourth quarter worth $260,000. Finally, BTC Capital Management Inc. increased its holdings in Jazz Pharmaceuticals by 9.4% in the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock valued at $6,115,000 after buying an additional 4,271 shares during the period. Institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total transaction of $116,350.00. Following the transaction, the chief executive officer now owns 439,307 shares of the company's stock, valued at approximately $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Seamus Mulligan bought 1,621 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now directly owns 101,621 shares of the company's stock, valued at $10,466,963. This trade represents a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders sold 19,623 shares of company stock worth $2,710,591 over the last ninety days. 4.20% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.